PMID: 6616231Aug 22, 1983Paper

Does acute L-DOPA increase active release of dopamine from dopaminergic neurons?

Brain Research
F PonzioS Algeri


L-DOPA is believed to be decarboxylated by the residual striatal dopaminergic presynaptic terminals with formation of the putative neurotransmitter dopamine (DA) and with increased availability of DA at post-synaptic receptors. However there is no direct evidence that the DA formed is released into the synaptic cleft. We therefore investigated the biochemical modifications occurring in the dopaminergic system after acute administration of L-DOPA. After acute L-DOPA (100 mg/kg plus 25 mg/kg of benserazide p.o.) the levels of 3-methoxytyramine (3-MT), a metabolite reflecting release of the neurotransmitter DA, were significantly raised, following the same pattern as DA levels, indicating that DA release from DA nerve terminals is increased after L-DOPA administration. The increased DA release and 3-MT formation were not reduced by pretreatment with direct DA agonists such as apomorphine (5 mg/kg i.p.) or piribedil (120 mg/kg p.o.). Thus in this case DA release is not under the control of the compensatory mechanisms induced by post-synaptic receptor hyperstimulation.


May 1, 1977·Proceedings of the National Academy of Sciences of the United States of America·L C Tang, G C Cotzias
Jan 1, 1977·Transactions of the American Neurological Association·H L KlawansW J Weiner
Nov 15, 1978·European Journal of Pharmacology·A M Di GiulioF Ponzio
Jan 1, 1975·Pharmacology & Therapeutics. Part B: General & Systematic Pharmacology·G Bartholini, A Pletscher
Jun 1, 1976·European Journal of Pharmacology·B H Westerink, J Korf
Jun 21, 1976·Naunyn-Schmiedeberg's Archives of Pharmacology·W Kehr
Sep 1, 1967·The Journal of Pharmacy and Pharmacology·N E AndénT Hökfelt
Oct 1, 1974·Life Sciences·O Hornykiewicz
Nov 1, 1972·European Journal of Pharmacology·H CorrodiU Ungerstedt
May 1, 1974·European Journal of Pharmacology·A JoriR Samanin
Oct 2, 1970·Science·K Y NgI J Kopin
May 15, 1971·Life Sciences. Pt. 1: Physiology and Pharmacology·U K RinneM Hyyppä
Jan 1, 1981·Naunyn-Schmiedeberg's Archives of Pharmacology·P C WaldmeierW J Richter
Jan 1, 1980·Psychopharmacology·O JenkinsD M Jackson
Feb 28, 1958·Science·A CARLSSONB WALDECK
Mar 1, 1980·Biochemical Pharmacology·K D WilnerY C Clement-Cormier

❮ Previous
Next ❯


Aug 1, 1996·Progress in Neurobiology·Y MisuH Okamura
Feb 1, 2003·Pharmacology & Therapeutics·Yoshimi MisuYoshio Goshima
Jun 1, 1990·British Journal of Pharmacology·N B MercuriG Bernardi

❮ Previous
Next ❯

Related Concepts

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.


Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.


Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.